AKKARAJU SRINIVAS 4
4 · Kalaris Therapeutics, Inc. · Filed May 22, 2026
Research Summary
AI-generated summary of this filing
Kalaris (KLRS) 10% Owner Dr. Srinivas Akkaraju Buys 244,300 Shares
What Happened
Dr. Srinivas Akkaraju (reported as a 10% owner) purchased 244,300 shares of Kalaris Therapeutics (KLRS) on May 20, 2026 at $4.83 per share for a total of $1,179,969. That acquisition was a privately negotiated purchase from Samsara BioCapital, L.P. (Samsara LP) (transaction code P). The filing also reports J-coded “other acquisition/disposition” entries on the same date: a disposition of 66,906 shares and acquisitions of 14,937 and 4,471 shares at no cash consideration — these reflect in‑kind distributions among related Samsara entities, not cash trades.
Key Details
- Transaction date(s): May 20, 2026. Purchase price: $4.83/share for 244,300 shares (total $1,179,969). (P = purchase)
- J-coded entries: 66,906 shares disposed; 14,937 and 4,471 shares acquired at $0 — these are pro rata, in‑kind distributions by Samsara LP (no cash exchanged).
- Beneficial ownership notes: Several footnotes state the shares are held by affiliated Samsara funds/entities. Dr. Akkaraju has voting and investment power over some of those entities and “may be deemed” to beneficially own the shares, but each reporting person disclaims ownership except to the extent of pecuniary interest.
- Filing timeliness: Report filed May 22, 2026 for transactions on May 20, 2026 — appears timely (filed within the typical two-business-day window).
- Shares owned after the transaction: Not specified in the summary data of this filing.
Context
- The primary item is a private purchase from an affiliated investor (Samsara LP), which is more informative than routine sales because it shows a cash purchase of company stock.
- The J-coded transfers are internal, in‑kind allocations among Samsara-related entities (not market sales or purchases) and do not necessarily reflect personal trading intent.
- As a reported 10% owner acting through/with affiliated funds, these transactions reflect institutional/fund-level movements and related transfer mechanics; they should be viewed differently from typical executive open‑market trades.
Insider Transaction Report
Form 4
AKKARAJU SRINIVAS
Director
Transactions
- Purchase
Common Stock
[F1][F2]2026-05-20$4.83/sh+244,300$1,179,969→ 2,224,147 total(indirect: By Samsara Opportunity Fund, L.P.) - Other
Common Stock
[F3][F4][F5]2026-05-20−66,906→ 10,657,028 total(indirect: By Samsara BioCapital, L.P.) - Other
Common Stock
[F6][F7]2026-05-20+14,937→ 14,937 total(indirect: By LLC) - Other
Common Stock
[F6][F8]2026-05-20+4,471→ 19,408 total(indirect: By Samsara BioCapital Partners, L.P.)
Footnotes (8)
- [F1]Represents the purchase of shares from Samsara BioCapital, L.P. ("Samsara LP") in a privately negotiated transaction.
- [F2]Securities are directly held by Samsara Opportunity Fund, L.P. ("Samsara Opportunity Fund"). Samsara Opportunity Fund GP, LLC ("Samsara Opportunity GP") is the general partner of Samsara Opportunity Fund and may be deemed to beneficially own the securities held by Samsara Opportunity Fund. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the securities held by Samsara Opportunity Fund and, accordingly, may be deemed to beneficially own the securities held by Samsara Opportunity Fund. Each of the Reporting Persons disclaims beneficial ownership in these securities except to the extent of its or his pecuniary interest therein.
- [F3]Represents a pro rata, in-kind distribution, without additional consideration, and not a purchase or sale of securities, by Samsara LP in respect of redeemed interests in Samsara LP. Of the shares distributed by Samsara LP, (i) 47,498 were distributed to redeeming limited partners, (ii) 14,937 shares were distributed to Samsara BioCapital GP, LLC ("Samsara LLC"), the general partner of Samsara LP, in respect of redeemed interests of non-managing members of Samsara LLC that were retained by Samsara LLC, and (iii) 4,471 shares were distributed to Samsara BioCapital Partners, L.P. ("Samsara BioCapital Partners"), in respect of the redeemed interest of a limited partner of Samsara LP that has been acquired by Samsara BioCapital Partners.
- [F4]The shares held by Samsara LP reflects the disposition of 244,300 shares, to Samsara Opportunity Fund as described in footnote (1), in which each of Samsara LLC and Dr. Akkaraju had no pecuniary interest.
- [F5]Securities are held by Samsara LP. Samsara LLC is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Akkaraju has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of the Reporting Persons disclaims beneficial ownership in these shares except to the extent of its or his respective pecuniary interest therein.
- [F6]Represents receipt of shares in the distribution in kind described in footnote (3).
- [F7]Securities are held by Samsara LLC. Dr. Akkaraju has voting and investment power over the shares held by Samsara LLC and, accordingly, may be deemed to beneficially own the shares held by Samsara LLC. Each of the Reporting Persons disclaims beneficial ownership in these shares except to the extent of its or his respective pecuniary interest therein.
- [F8]Securities are held by Samsara BioCapital Partners. Dr. Akkaraju has voting and investment power over the shares held by Samsara BioCapital Partners and, accordingly, may be deemed to beneficially own the shares held by Samsara BioCapital Partners. Each of the Reporting Persons disclaims beneficial ownership in these shares except to the extent of its or his respective pecuniary interest therein.